ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, today announced that it has signed an agreement to acquire Positron Precision GmbH, a company developing a technology platform for positron emission tomography (PET) tracers and various radiotherapeutic candidates. As a result of the transaction, ITM will be able to develop next-generation “shake and inject” cold kits to target a broad range of indications, thereby further strengthening its position in the field of radiodiagnostics. In addition, the transaction will add new therapeutic candidates to ITM’s robust radiotherapeutic oncology pipeline.
To
read more please visit:
ITM
Acquires a New Platform for the Development of Next-Generation Theranostics
Source: ITM